These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8385595)

  • 1. Plasma ANP and cGMP levels in CAPD patients.
    Lauster F; Heim JM; Drummer C; Gerzer R; Schiffl H
    Contrib Nephrol; 1993; 101():44-50. PubMed ID: 8385595
    [No Abstract]   [Full Text] [Related]  

  • 2. Intraindividual comparison of ANP, cGMP and plasma catecholamines between HD and CAPD.
    Plum J; Ziyaie M; Kemmer FW; Passlick-Deetjen J; Grabensee B
    Adv Perit Dial; 1990; 6():211-9. PubMed ID: 1982811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cGMP level as a marker of the hydration state in renal replacement therapy.
    Lauster F; Heim JM; Drummer C; Fülle HJ; Gerzer R; Schiffl H
    Kidney Int Suppl; 1993 Jun; 41():S57-9. PubMed ID: 8391608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial natriuretic peptide and cyclic guanosine-monophosphate in children and adolescents on peritoneal dialysis.
    Bald M; Bonzel KE; Rascher W
    Clin Nephrol; 1994 Jul; 42(1):50-3. PubMed ID: 7923967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial natriuretic peptide and cyclic 3'5'-guanosine monophosphate as indicators of fluid volume overload in children with chronic renal failure.
    Lettgen B; Bald M; Valleé H; Bonzel KE; Rascher W
    Pediatr Nephrol; 1992 Jan; 6(1):60-4. PubMed ID: 1311187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease.
    Osajima A; Okazaki M; Kato H; Anai H; Tsuda Y; Segawa K; Tanaka H; Tamura M; Takasugi M; Nakashima Y
    Am J Nephrol; 2001; 21(2):112-9. PubMed ID: 11359018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial natriuretic peptide (ANP) is removed by peritoneal dialysis in humans.
    Fincher ME; Campbell HT; Sklar AH; Caruana RJ; Lightfoot BO; Cheek PL; Smith KL; Hess CP
    Adv Perit Dial; 1989; 5():16-9. PubMed ID: 2577402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of subtypes of hypertension in CAPD patients by cyclic guanosine monophosphate.
    Lang SM; Wolfram G; Gerzer R; Schiffl H
    Perit Dial Int; 1999; 19(2):143-7. PubMed ID: 10357185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluid status in haemodialysed patients.
    Leunissen KM
    Nephrol Dial Transplant; 1995; 10(2):153-5. PubMed ID: 7753445
    [No Abstract]   [Full Text] [Related]  

  • 10. The postdialytic plasma cyclic guanosine 3':5'-monophosphate level as a measure of fluid overload in chronic hemodialysis.
    Lauster F; Fülle HJ; Gerzer R; Schiffl H
    J Am Soc Nephrol; 1992 Mar; 2(9):1451-4. PubMed ID: 1320949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant increase in plasma atrial natriuretic peptide and cyclic GMP during volume loading.
    Weil J; Lang RE; Suttmann H; Rampf U; Bidlingmaier F; Gerzer R
    Klin Wochenschr; 1985 Dec; 63(24):1265-8. PubMed ID: 3003451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of dry weight in haemodialysis patients by the volume markers ANP and cGMP.
    Wolfram G; Sitter T; Gottsmann M; Gerzer R; Schiffl H
    Nephrol Dial Transplant; 1996; 11 Suppl 2():28-30. PubMed ID: 8803991
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma levels of human atrial natriuretic factor in patients treated by hemodialysis and continuous ambulatory peritoneal dialysis.
    Ando R; Matsuda O; Miyake S; Yoshiyama N
    Nephron; 1988; 50(3):225-8. PubMed ID: 2976122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma levels of atrial natriuretic peptide and cyclic guanosine monophosphate in patients with heart diseases.
    Nakaoka H; Imataka K; Kitahara Y; Fujii J; Ishibashi M; Yamaji T
    Jpn Circ J; 1988 Jan; 52(1):30-4. PubMed ID: 2834571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modification of atrial natriuretic peptide (ANP) and cyclic GMP by hemofiltration and hemodialysis].
    Eisenhauer T; Talartschik J; Quentin E; Kreutzfeldt W; Scheler F
    Klin Wochenschr; 1988 Sep; 66(18):940-5. PubMed ID: 2846948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluid balance in patients with chronic renal failure assessed with N-terminal proatrial natriuretic peptide, atrial natriuretic peptide and ultrasonography.
    Metry G; Hall C; Wikström B; Källskog V; Hansell P; Danielson B
    Acta Physiol Scand; 2001 Feb; 171(2):117-22. PubMed ID: 11350271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of digoxin on atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and cyclic 3', 5'-guanosine monophosphate (cGMP) in patients with chronic congestive heart failure].
    Kobusiak-Prokopowicz M; Swidnicka-Szuszkowska B; Mysiak A
    Pol Arch Med Wewn; 2001 Jun; 105(6):475-82. PubMed ID: 11865578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of dry body-weight in haemodialysis patients by the biochemical marker cGMP.
    Lauster F; Gerzer R; Weil J; Fülle HJ; Schiffl H
    Nephrol Dial Transplant; 1990; 5(5):356-61. PubMed ID: 2165225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha-atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock.
    Hartemink KJ; Groeneveld AB; de Groot MC; Strack van Schijndel RJ; van Kamp G; Thijs LG
    Crit Care Med; 2001 Jan; 29(1):80-7. PubMed ID: 11176165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment.
    Franz M; Woloszczuk W; Hörl WH
    Kidney Int; 2000 Jul; 58(1):374-83. PubMed ID: 10886584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.